Results 101 to 110 of about 59,883 (231)
FEBS Open Bio, Volume 16, Issue 5, Page 921-931, May 2026.NF90–NF45 functions as a negative regulator of methyltransferase‐like 3/14 (METTL3/14)‐mediated N6‐methyladenosine (m6A) modification on primary microRNAs (pri‐miRNAs). NF90–NF45 binds to anti‐oncogenic pri‐miRNAs and inhibits their m6A modification, thereby suppressing the biogenesis of anti‐oncogenic miRNAs.
Takuma Higuchi +6 more
wiley +1 more source
Celecoxib in breast cancer prevention and therapy. [PDF]
, 2018 Breast cancer has a high incidence worldwide. The results of substantial studis reveal that inflammation plays an important role in the initiation, development, and aggressiveness of many malignancies. The use of celecoxib, a novel NSAID, is repetitively
Cao, Wei +4 more
core
American Journal of Hematology, Volume 101, Issue 5, Page 1025-1035, May 2026.ABSTRACT Mantle cell lymphoma (MCL) is a B‐cell malignancy with a chronically relapsing clinical course and pronounced genetic heterogeneity. To investigate the clonal dynamics underlying early disease relapse, we performed single‐cell RNA sequencing of paired tumor samples collected at diagnosis and at first relapse. Inference of copy number variants (
Dmitry Manakov +14 more
wiley +1 more source
PLoS ONE, 2020 Treating pancreatic ductal adenocarcinoma (PDAC) remains a major hurdle in the field of oncology. Less than half of patients respond to frontline chemotherapy and the pancreatic tumor microenvironment limits the efficacy of immunotherapeutic approaches ...
Matthew Brown +10 more
doaj +1 more source
Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors. [PDF]
, 2014 BackgroundIn 31 solid tumor patients treated with the demethylating agent decitabine, we performed tumor biopsies before and after the first cycle of decitabine and used immunohistochemistry (IHC) to assess whether decitabine increased expression of ...
A Kumari +55 more
core +2 more sources
Chinese Journal of Cancer Research, 2003 As a new member of IAP (inhibitors of apoptosis protein) family, survivin has potent anti-apoptotic activities, and involves in the mitosis and angiogenesis. Researches have demonstrated that surviving is a tumor-specific anti-apoptotic factor, expressed in fetal tissues, and common human cancers, while not in normal, terminally differentiated adult ...
Wen-zhe Song +3 more
openaire +1 more source
Clinical and Translational Medicine, Volume 16, Issue 5, May 2026.• XPO1 hyperactivation promotes leukaemogenesis by altering nucleocytoplasmic transport and transcriptional control in acute myeloid leukaemia (AML). • Selinexor and eltanexor show preferential activity in NPM1‐mutated, DEK::NUP214‐positive and SF3B1‐mutated myeloid neoplasms.
Yifan Liu +4 more
wiley +1 more source
Pulmonary Circulation, 2019 The reversibility of pulmonary arterial hypertension (PAH) determines the operability of congenital heart disease (CHD) complicating with PAH, but it lacks a method for evaluating the reversibility.
Gang Li +7 more
doaj +1 more source
Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance [PDF]
, 2016 Resistance formation after initial therapy response (acquired resistance) is common in high-risk neuroblastoma patients. YM155 is a drug candidate that was introduced as a survivin suppressant.
A Rauch +42 more
core +1 more source
Archives of Pathology & Laboratory Medicine, 2003 Abstract Context.—Survivin is a novel inhibitor of apoptosis that acts via a pathway independent of bcl-2. Little is known about its distribution in brain tumors or how it correlates with other biomarkers of malignancy, such as telomerase, an enzyme that plays a critical role in cellular immortalization and cancer biology.
B. K. Kleinschmidt-DeMasters +6 more
openaire +1 more source